drugset / Trial / NCT02818751

Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents With Anxiety

NCT02818751

RandomizedParallel-groupDouble-blindTreatment

Summary

Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents with Anxiety. To determine the effects of escitalopram on functional activation patterns during a Continuous Performance Task with Emotional and Neutral Distracters, the CPT-END. To examine baseline functional activity and functional connectivity profiles in the ventrolateral prefrontal cortex as markers of subsequent treatment response to escitalopram in adolescents with generalized anxiety disorder (GAD). To use proton magnetic resonance spectroscopy (1H MRS) to examine glutamatergic and γ-aminobutyric acid (GABA)-related abnormalities in the anterior cingulate in adolescents with GAD as compared to healthy adolescents.

Timeline

Start
2015-05
Primary completion
2019-05
Completion
2020-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Escitalopram Small molecule 15 mg Oral
Subject Escitalopram Small molecule 20 mg Oral

Indications